Experts Say Interpretable Results Unlikely In Burzynski’s Antineoplastons Studies
Special Report: Politicla Pressure, System Loopholes, Enabled Burzynski To Avoid Usuals
Scientific Process
“Unfortunate Result Of Burzynski’s Practice Over Two Decades: Thousands Of Patients, Not Enough Data” To Determine Safety, Efficacy, FDA Says
Reviewers Note Major Flaws In Design Of Burzynski’s Trials
Interview: Burzynski Explains Why He Calls Treatment “Non-Toxic”
Case Study: The Post-Surgical Treatment Of A Child With Medulloblastoma At The Burzynski Clinic
Trending Stories
- Richard Pazdur left FDA to avoid being part of “the destruction of the American medical system”
- Harvey Risch, critic of COVID-19 response, tapped by White House to serve as chair of the President’s Cancer Panel
- Brown University reaches agreement with Trump administration to restore funding
- Pediatric cancer five-year survival rate has increased dramatically, AACR says in inaugural Pediatric Cancer Progress Report
- Antonio Wolff, Mikala Egeblad named co-directors of Johns Hopkins Kimmel Cancer Center Breast and Gynecologic Cancer Program
- John Byrd brings blood cancer expertise to solid tumor, immunology powerhouse at UPMC
